Dogwood Therapeutics, Inc.
DWTX
$5.37
$1.1025.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 522.31% | 96.20% | -20.20% | -8.42% | 2.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 562.70% | 80.59% | -27.58% | -15.62% | -45.54% |
| Operating Income | -562.70% | -80.59% | 27.58% | 15.62% | 45.54% |
| Income Before Tax | -600.54% | -84.66% | 27.14% | 14.87% | 46.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -600.50% | -84.66% | 27.14% | 14.87% | 46.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -600.50% | -84.66% | 27.14% | 14.87% | 46.04% |
| EBIT | -562.70% | -80.59% | 27.58% | 15.62% | 45.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -339.17% | -27.02% | 41.42% | 18.97% | 48.64% |
| Normalized Basic EPS | -311.79% | -27.02% | 41.42% | 18.97% | 48.64% |
| EPS Diluted | -339.17% | -27.02% | 41.42% | 18.97% | 48.64% |
| Normalized Diluted EPS | -311.79% | -27.02% | 41.42% | 18.97% | 48.64% |
| Average Basic Shares Outstanding | 70.13% | 45.37% | 24.37% | 5.06% | 5.06% |
| Average Diluted Shares Outstanding | 70.13% | 45.37% | 24.37% | 5.06% | 5.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |